NCT01891357View on ClinicalTrials.gov

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 16, 2016

Study Completion Date

November 16, 2016

Conditions
Carcinoma, Ductal, Breast
Interventions
PROCEDURE

Biopsy before and after three weeks of study treatment

Core biopsies for histological analyses, to be analysed by the central pathology

DRUG

paclitaxel

DRUG

lapatinib

DRUG

trastuzumab

Trial Locations (10)

10713

Praxis für gynäkologische Onkologie am Brustzentrum City, Berlin

44309

Klinikum Westfalen GmbH - Knappschaftskrankenhaus, Dortmund

47053

Bethesda Krankenhaus, Senologie, Duisburg

49124

Niels-Stensen-Kliniken, Georgsmarienhütte

51067

Krankenhaus Köln Holweide, Brustzentrum, Cologne

59073

St. Barbara-KIinik, Hamm

65929

Klinikum Frankfurt Höchst, Frankfurt am Main

73730

Klinikum Esslingen, Esslingen am Neckar

74078

SLK Kliniken, Heilbronn

09116

Klinikum Chemnitz gGmbH, Chemnitz

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

West German Study Group

OTHER